Click here to get sample of the premium reporthttps://www.quincemarketinsights.com/request-sample-60943?utm_source=campaign=Pooja/AZ

The report commences with brief information of the globalBiotechnology media, sera and reagentsmarket. This report sets the tone for the rest of the report, providing users the scope of the report. The report includes important facts and statistics on the globalBiotechnology media, sera and reagentsmarket.

A globalBiotechnology media, sera and reagentsmarket is provided in this next section. This involves market introduction and a standard product definitionBiotechnology media, sera and reagents. This section provides readers with market value and year-by-year growth. Annual growth gives readers a wider view of growth patterns during the forecast period.

The report focuses on macro-economic, demand and supply drivers, constraints, and important patterns. In order to better inform the decision-making system of clients, the impact analysis for weighted average model-based growth drivers is present in the report.

The report will be updated on a number of market opportunities, which leadingBiotechnology media, sera and reagentscompanies can benefit from, to provide readers with up-to-date information on the latest developments on the globalBiotechnology media, sera and reagentsmarket. As the healthcare sector develops continuously, it is vital forBiotechnology media, sera and reagentsmanufacturers to develop key business strategies to keep a track of current developments and trends. This section provides detailed insights into the sourcing of raw materials, supply chain, regulatory approvals, price analyses, list of distributors and cost structure.

Considering the broad spectrum of the internationalBiotechnology media, sera and reagentsmarket, QMIs report provides important insights, analysis and forecast segmentation. Data are divided into product type, method, technology and region on the globalBiotechnology media, sera and reagentsmarket. This segment-specific analysis also offers a country-specific forecast taking all key parameters of the globalBiotechnology media, sera and reagentsmarket into consideration.

The last section of the report covers the competitive landscape of the globalBiotechnology media, sera and reagentsmarket to give readers an overview of company analysis and market players. This competitive intelligence is based on the categories of suppliers throughout the entire value chain and their participation in the globalBiotechnology media, sera and reagentsmarket.

QMI is committed to providing its clients with impartial and independent solutions for market research. Each QMI report is assembled after an extensive and comprehensive research. In order to give you the most comprehensive and accurate information, we use a mix of proven and innovative methodology. Primary research, secondary research, business research, focused interviews and social media analysis are our main sources of research.

Get Scope of the actual premium reporthttps://www.quincemarketinsights.com/request-toc-60943?utm_source=campaign=Pooja/AZ

Market Segmentation:

By Type: Media Sera ReagentBy Application: Cancer Research Biopharmaceuticals Regenerative Medicine & Tissue Engineering OthersBy End-User: Biotechnology & Pharmaceutical Companies Academic Institute Research LaboratoryBy Region: North America North America, by CountryUSCanadaMexico North America, by Type North America, by Application North America, by End-User Western Europe Western Europe, by CountryGermanyUKFranceItalySpainThe NetherlandsRest of Western Europe Western Europe, by Type Western Europe, by Application Western Europe, by End-User Asia Pacific Asia Pacific, by CountryChinaIndiaJapanSouth KoreaAustraliaIndonesiaRest of Asia Pacific Asia Pacific, by Type Asia Pacific, by Application Asia Pacific, by End-User Eastern Europe Eastern Europe, by CountryRussiaTurkeyRest of Eastern Europe Eastern Europe, by Type Eastern Europe, by Application Eastern Europe, by End-User Middle East Middle East, by CountryUAESaudi ArabiaQatarIranRest of Middle East Middle East, by Type Middle East, by Application Middle East, by End-User Rest of the World Rest of the World, by CountrySouth AmericaAfrica Rest of the World, by Type Rest of the World, by Application Rest of the World, by End-User

Major Companies:

Key Players:GE Healthcare, Bio-Rad laboratories Inc., Merck KGaA (Sigma Aldrich), Sartorius AG, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd, Merck & Co., Inc.

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us

Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109,Pune, Maharashtra 411028Phone: +91 706 672 5858/+1 208 405 2835/+91 706 672 4848Email:sales@quincemarketinsights.comWeb:www.quincemarketinsights.com

Read more:
Biotechnology Media, Sera and Reagents Market Study and Future Prospect | Forecast To 2028 - Azizsalon News

By Dina Bass

Sujal Patels data storage company, Isilon Systems, was one of the only tech startups to raise investment funds in the dark winter of Seattles early 2000s dot-com bust. Now, hes announcing hes raised money for a second company, in biotech this time, in the midst of a global pandemic.

I think I only perform well under pressure, Patel said. In his latest venture, called Nautilus Biotechnology, hes tackling a more difficult problem than computer storage. The goal is to build a device that can map patients proteins more rapidly and cheaply, allowing drug developers to use that data to find targeted treatments for diseases like cancer, and let doctors monitor flare-ups of conditions like multiple sclerosis.

Nautilus has largely kept its work quiet since it was founded in 2016, but on Thursday the company said it raised $76 million, bringing its total funding to more than $108 million. The round was led by Vulcan Capital, the investment house of the late Microsoft co-founder Paul Allen, and was joined by Jeff Bezoss family office.

Patel met the co-founder of Nautilus, Parag Mallick, while still at Isilon. Mallick was a working on using supercomputers to detect cancer through detailed blood analysis at Cedars-Sinai Medical Center in Los Angelesand Patel was selling him the gear needed to store the vast volumes of data created in his research.

In 2010, Isilon was acquired by storage giant EMC Corp. for $2.25 billion. Soon, Patel and his wife became donors to Mallicks lab when he moved to Stanford University. In 2016, Mallick called Patel to pitch him on a new idea he had for a technique to use machine learning to make the mapping of patients proteins as easy and affordable as genome-measuring has become. Patel signed on as an investor, co-founder and chief executive officer. Mallick is the companys chief scientist.

Nautilus has high hopes for the potential impact of studying proteins. The human genome itself is a set of instructions for how the body should operate, and proteins are how those instructions are expressed, changing in response to triggers like aging. The high cost and slow pace of mapping them has really been a bottleneck to all of biology, particularly to how we develop drugs and how we diagnose people, Mallick said.

When researching drugs, pharmaceutical companies want to find proteins that are common in diseased cells but not in healthy cells. They can then create a drug that attacks that protein and leaves healthy cells alone. Right now with the tools that exist, its harder to find those targets, Mallick said. Nautiluss technology would use machine learning to study the human proteome, which is the complete set of proteins expressed by an organism.

Other companies working on proteomics include Seer, a startup that has raised more than $108 million. Nautilus does not yet have a working device.

Vulcan Capital knows how hard this space isa previous investment in proteomics didn't provide a great return, said Stuart Nagae, director of venture capital at the firm. But the experience convinced him that theres potential there, and Nagae said hes impressed by Nautilus. "It is early but they have an incredibly thoughtful approach," he said. "This is a fundamentally transformative opportunity that you don't see very often."

See the original post here:
Jeff Bezos's family office bets on Sujal Patel's startup that is mapping human proteins - ETtech.com

A Research study on Red Biotechnology Market analyzes and offers ideas of exhaustive research on ancient and recent Red Biotechnology market size. Along with the estimated future possibilities of the market and emerging trends in the Red Biotechnology market.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/18591

The report on Red Biotechnology market is an all-inclusive study of the current scenario of the industry and its growth prospects over 2025. The report is a meticulous endeavor to present a comprehensive overview of Red Biotechnology market based on growth opportunities and market shares. The report presents a detailed outline of the product type, key manufacturers, application and key regions concerned in the Red Biotechnology market.

This report considers various parameters to calculate the Red Biotechnology market size especially, value and volume generated from the sales in such segments as product type, application, region, competitive landscape etc.

The competitive scenario of the Red Biotechnology market has also been evaluated by the report while presenting detailed analysis of notable manufacturers and vendors participating in the Red Biotechnology market.

Major companies covered in the Red Biotechnology market report are as follows:

Red Biotechnology market has been segmented by product type as follow:

Antibody, Nucleic Acid, Protein and Other

Red Biotechnology market has been segmented by application type as follow:

Biopharmaceutical Production, Gene Therapy and Pharmacogenomics and Genetic Testing

Additionally, the report discusses key trends driving the growth of the market, opportunities involved, major challenges and risks that are often confronted by key manufacturers besides presenting an overall idea of the market. The report also analyses in details emerging trends in the marketplace and their impact on current and future development of the Red Biotechnology market.

Research objectives of the study included the analysis of global Red Biotechnology market consumption in terms of volume and value based on parameters such as regions, application and product type based on data and forecast for the period of 2025. In an effort to describe, define and analyze the volume, value, market share, sales, competitive landscape, development plans and SWOT analysis for the ensuing years, the report focuses on key manufacturers and their actions in Red Biotechnology market.

The report analyses Red Biotechnology in respect to growth trends, future prospects and contribution of individual players in the Red Biotechnology market. It also reveals detailed information about the growth potential, drivers, opportunities, risks and challenges that influence the development of Red Biotechnology market. The report presents a comprehensive projection of the regional submarkets of Red Biotechnology along with the key countries where the submarkets are most dominant. It also analyses developments such as new product launches, agreements, acquisitions and expansions as well as provides strategic profiles of key players in Red Biotechnology market while highlighting their growth strategies.

An overview of Red Biotechnology market segmentation

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/18591

Read the original:
Red Biotechnology Market Research, Recent Trends and Growth Forecast 2025 - ZZReport

A perfect mix of quantitative & qualitative Agriculture Biotechnologymarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Agriculture Biotechnologymarket. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

The Agriculture BiotechnologyMarket report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Agriculture BiotechnologyIndustry.

Downlaod Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6319455/agriculture-biotechnology-market

The Top players are ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto, .

Market Segmentation:

On the basis of the end users/applications, Transgenic crops market, Synthetic biology-enabled products market

Download Free Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6319455/agriculture-biotechnology-market

Be the first to knock the door showing the potential that Agriculture Biotechnologymarket is holding in it. Uncover the Gaps and Opportunities to derive the most relevant insights from our research document to gain market size.

A major chunk of this Global Agriculture BiotechnologyMarket research report is talking about some significant approaches for enhancing the performance of the companies. Marketing strategies and different channels have been listed here. Collectively, it gives more focus on changing rules, regulations, and policies of governments. It will help to both established and new startups of the market.

The study objectives of this report are:To analyze global Agriculture Biotechnologystatus, future forecast, growth opportunity, key market, and key players.To present the Agriculture Biotechnologydevelopment in the United States, Europe, and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market, and key regions.

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6319455/agriculture-biotechnology-market

Major Points from Table of Contents

1 Agriculture Biotechnology Agriculture Biotechnology Market Overview2 Agriculture Biotechnology Market Competition by Manufacturers3 Production Capacity by Region4 Global Agriculture Biotechnology Market by Regions5 Production, Revenue, Price Trend by Type6 Global Agriculture Biotechnology Market Analysis by Application7 Company Profiles and Key Figures in Agriculture Biotechnology Business8 Agriculture Biotechnology Manufacturing Cost Analysis9 Marketing Channel, Distributors and Customers10 Market Dynamics11 Production and Supply Forecast12 Consumption and Demand Forecast13 Forecast by Type and by Application (2021-2026)14 Research Finding and Conclusion15 Methodology and Data Source.

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6319455/agriculture-biotechnology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

See more here:
Agriculture Biotechnology Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top...

Shire

All of the product type and application segments of the Nanoparticles in Biotechnology and Pharmaceuticals market included in the report are deeply analyzed based on CAGR, market size, and other crucial factors. The segmentation study provided by the report authors could help players and investors to make the right decisions when looking to invest in certain market segments.

The Essential Content Covered in the Nanoparticles in Biotechnology and Pharmaceuticals Market Report :

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report is a compilation of different studies, including regional analysis where leading regional Nanoparticles in Biotechnology and Pharmaceuticals markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Nanoparticles in Biotechnology and Pharmaceuticals market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Nanoparticles in Biotechnology and Pharmaceuticals markets. It also provides information on lucrative opportunities available in key regional Nanoparticles in Biotechnology and Pharmaceuticals markets.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=001

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Nanomagnetic Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original here:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and...

Turning Point Therapeutics Inc (TPTX) is near the middle in its industry group according to InvestorsObserver. TPTX gets an overall rating of 62. That means it scores higher than 62 percent of stocks. Turning Point Therapeutics Inc gets a 59 rank in the Biotechnology industry. Biotechnology is number 10 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 62 means the stock is more attractive than 62 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Turning Point Therapeutics Inc (TPTX) stock is down -10.92% while the S&P 500 is up 0.05% as of 11:03 AM on Tuesday, May 19. TPTX has fallen -$6.98 from the previous closing price of $63.90 on volume of 950,134 shares. Over the past year the S&P 500 is higher by 4.05% while TPTX is up 56.02%. TPTX lost -$3.49 per share the over the last 12 months.

To screen for more stocks like TPTX click here.

More here:
Is Turning Point Therapeutics Inc (TPTX) a Winner in the Biotechnology Industry? - InvestorsObserver

Biotechnology as a service Market Research Report How Effective in Covid-19 with latest technology, growth rate, prices, market size, trading, and key vendors of the industrys information with forecast from 2020 to 2027. This research report also combines industry-wide statistically relevant quantitative data and relevant and insightful qualitative analysis. This report has published stating that the global Biotechnology as a service Market is anticipated to expand significantly at Million US$ in 2020 and is projected to reach Million US$ by 2027, at a CAGR of during the forecast period.

A complete study of the competitive landscape of the global Biotechnology as a service Market has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This study also provides an in-depth analysis of the global market with future estimates to identify current trends and investment trends for the forecast year 2020-2027.

Request Sample Copy of this Report @: https://www.healthcareintelligencemarkets.com/request_sample.php?id=112299

Some of the key players operated in this report are:

Tissue Analytics, ARANZ Medical Limited, eKare, Inc.,WoundMatrix, Inc.,WoundZoom Inc., Kent Imaging Inc.,WoundRight Technologies, LLC, WoundVision, LL, Hitachi Healthcare Americas, Smith & Nephew plc.

Reasons for Buying this Report:

Factors that drive global opportunities have been surveyed in this research report to understand the current and prospective growth of the businesses. This study also offers an in-depth analysis of the global market with future estimates to identify current trends and investment trends for the forecast year 2020-2027.

Get Up To 40% Discount on this Premium Report @: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=112299

Regional Analysis:

Finally, all aspects of the global Biotechnology as a service Market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

Major TOC points:

For More Information: https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=112299

*If you need anything more than these then let us know and we will prepare the report according to your requirement.

About Us:

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare industries. Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Contact Us:

Marvella Lit

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: [emailprotected]

Web: http://www.healthcareintelligencemarkets.com

Phone: +44-753-712-1342

Read more:
Biotechnology as a service Market Projected to Witness Vigorous Expansion over Covid-19 by 2020 with Major Vendors like Tissue Analytics, ARANZ...

COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

Research Report onBiotechnology/Pharmaceutical Services Outsourcing Market size | Industry Segment by Applications (Regenerative Medicine, Biobanking and Drug Discovery), by Type (Consulting, Auditing & Assessment, Regulatory Affairs, Product Maintenance, Product Design & Development, Product Testing & Validation, Training & Education and Others), Regional Outlook, Market Demand, Latest Trends, Biotechnology/Pharmaceutical Services Outsourcing Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/3489

The recent study on the Biotechnology/Pharmaceutical Services Outsourcing market consists of data related to this industry vertical, with regards to certain parameters. The Biotechnology/Pharmaceutical Services Outsourcing market research focuses on providing an in-depth summary of this industry, explicitly revealing the Biotechnology/Pharmaceutical Services Outsourcing market industry size and share, segmentation of application, product types, along with new opportunities in the business space.

Vital information regarding important competitors in this industry is inculcated in the report. Furthermore, details regarding regions that have received highest returns is also incorporated. The report also speaks about the Biotechnology/Pharmaceutical Services Outsourcing market plans to deliver a highly bifurcated overview of this industry, with regards to its present and future scenarios.

Biotechnology/Pharmaceutical Services Outsourcing Market competition by top Manufacturers:

Influential factors and challenges of the Biotechnology/Pharmaceutical Services Outsourcing market:

Region-based assessment of business along with its influence on the Biotechnology/Pharmaceutical Services Outsourcing market:

Biotechnology/Pharmaceutical Services Outsourcing Market Classification by Types:

Biotechnology/Pharmaceutical Services Outsourcing MarketSize by End user Application:

An analysis of the Biotechnology/Pharmaceutical Services Outsourcing market:

Point to Point Analysis of Biotechnology/Pharmaceutical Services Outsourcing Market from Table of Contents are as Follows:

1 Scope of the Report

2 Executive Summary

3 Market Drivers, Challenges and Trends

4 Marketing, Distributors and Customer

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/3489

See original here:
Biotechnology/Pharmaceutical Services Outsourcing Market Research, Recent Trends and Growth Forecast 2025 - ZZReport

Westport, CT, May 07, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company) today appointed Mr. Michael Schmertzler to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc.

Mr. Schmertzler has been the Chairman of the board of directors of PTC Therapeutics, Inc. since 2004, where he was a founding institutional investor. He has been actively involved in biotechnology as an investor and investment banker since founding Morgan Stanleys biotechnology industry practice in 1989. He is also now a director of privately held SHY Therapeutics and previously served as CEO of a Yale University biotechnology spin-off and as a director of Cytokinetics and Idenix.

Mr. Schmertzler is currently the independent director of Lehman Commercial Paper, Inc., the largest subsidiary of the liquidating post-bankruptcy Lehman Brothers estate. Since 1998, he has also taught private equity courses at Yale University. Previously he was the President of the Morgan Stanley Leveraged Capital Funds and later Co-Head of Credit Suisse First Boston Equity Partners. Mr. Schmertzler has also been a Managing Director in the Mergers and Acquisitions Department of Morgan Stanley and headed its global insurance industry practice. He was head of international investment banking and capital markets of Shearson Lehman Brothers and, prior to its acquisition in 1984 by American Express, was the Chief Financial Officer and an investment banker at Lehman Brothers.

In addition to his biotechnology board positions, Mr. Schmertzler has served as a director or lead investor at Cain Chemical, Colt Industries, Segway and other industrial and technology companies. Mr. Schmertzler received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History, and City Planning, and an M.B.A. from the Harvard Business School.

Michaels experience in leading early stage biotech companies makes him uniquely qualified to join our Board. We look forward to learning from Michael as we progress towards our mission to bring an effective anti-viral therapy to patients, commented Jerome Zeldis, M.D., Ph.D, Executive Chair of ViralClear Pharmaceuticals, Inc.

Mr. Schmertler joins the former Chief Medical Officer of Celgene Jerome Zeldis, M.D., Ph.D, Nick Spring, CEO of ViralClear and a former senior executive at Merck & Co., Anthony Zook, former senior executive at Astra Zeneca, Plc and Dennis Purcell, the founder of Aisling Capital on the Board of ViralClear.

I am very pleased to have the opportunity to contribute to the development of this young anti-viral company. The merimepodib findings to date are compelling, and I look forward to working with the ViralClear team at such a pivotal time for the global community, commented Mr. Schmertzler.

About merimepodibAnti-viral candidate merimepodib (MMPD) targets RNA-dependant polymerases. The molecule has shown activity against a broad spectrum of RNA viruses and has demonstrated satisfactory safety data from over 300 patients treated for hepatitis C. Recently, the Company published first pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. The Company recently submitted two manuscripts titledThe IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro and The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications. The manuscripts were authored by Natalya Bukreyeva, Emily K. Mantlo, Rachel A. Sattler, Cheng Huang, John T. Manning, Slobodan Paessler, DVM, Ph.D of the UTMB Galveston National Laboratory and Jerome Zeldis, M.D., Ph.D of ViralClear. In-vitro studies referenced in the manuscript demonstrated that merimepodib decreased viral production by over 98%.

About BioSig TechnologiesBioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Companys first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About ViralClearBioSigs subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat COVID-19. Merimepodib is intended to be an orally administered, broad-spectrum anti-viral agent that has demonstrated strong activity against COVID-19 in cell cultures in laboratory testing. The product candidate has completed Phase I and three Phase II trials in other indications.

Forward-looking StatementsThis press release contains forward-looking statements. Such statements may be preceded by the words intends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Companys control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Companys filings with the Securities and Exchange Commission (SEC), including the Companys Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SECs website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Go here to see the original:
Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc. - GlobeNewswire

Airbus and Koniku Inc. have made a significant step forward in the co-development of a solution for aircraft and airport security operations by extending research activities to include biological hazard detection capabilities, as well as chemical and explosive threats.

The disruptive biotechnology solution, which was originally focused on the contactless and automated detection, tracking and location of chemicals and explosives on-board aircraft and in airports, is now being adapted in light of the COVID-19 crisis to include the identification of biological hazards.

Based on the power of odor detection and quantification found in nature, the technical solution, developed to meet the rigorous operational regulatory requirements of aircraft and airport security operations, uses genetically engineered odorant receptors that produce an alarm signal when they come into contact with the molecular compounds of the hazard or threat that they have been programmed to detect.

Airbus and Koniku Inc. entered into a cooperation agreement in 2017, leveraging Airbus expertise in sensor integration and knowledge of ground and on-board security operations within the aviation and defense industries, as well as Konikus biotechnology know-how for automated and scalable volatile organic compound detection (via their Konikore platform).

With in-situ testing planned for Q4 2020, Airbus is demonstrating its ability to accelerate traditional research cycles in a real-time environment in order to develop and bring to market a game-changing, end-to-end, security solution at convincing scale and speed, thereby contributing to the continuous improvement of security in the air transport ecosystem, while increasing operational efficiency and improving passenger experience.

Originally posted here:
Airbus and Koniku Inc. Embark on Disruptive Biotechnology Solutions for Aviation Security Operations - I-Connect007

TUSTIN, Calif. and MORGAN HILL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, and Aragen Bioscience, a leading contract research organization (CRO) focused on accelerating pre-clinical biologics product development, today announced a co-marketing agreement that will provide clients an integrated sequence-to-manufacturing service. Under terms of the non-exclusive agreement, the companies will offer customers Aragens cell line development expertise integrated with Avids upstream and downstream process development and analytical services to drive efficiencies and reduce overall timelines for delivering CGMP bulk drug substances.

With pharmaceutical and biotechnology companies focused on delivering their innovative medicines to patients as quickly as possible, this alliance aims to speed the entire CGMP manufacturing process by having a single, integrated team oversee a single, integrated project timeline with significant built-in process efficiencies, saidTimothy Compton, chief commercial officer of Avid. We view this collaboration with Aragen as a significant win for current and future clients of both companies and we are excited to contribute our deep CDMO expertise to the partnership, particularly our more than 15 years of commercial product manufacturing experience.

I am excited about this partnership that will enable us to accelerate drug development timelines and deliver new biologic therapeutics to patients faster by integrating two best-in-class offerings to our customers, said Axel Schleyer, CEO of Aragen. Our services in discovery, cell line development, which includes our innovative RapTr platform, protein production and preclinical testing are a great match with Avids clinical and commercial manufacturing capabilities. We look forward to this collaboration that advances novel ideas into breakthrough medicines.

AboutAvid Bioservices, Inc.

Avid Bioservicesis a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.www.avidbio.com

About Aragen Bioscience, Inc.

Aragen Bioscience, Inc., a wholly owned subsidiary of GVK BIO, is a leading contract research organization based in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of in vitro and in vivo services for the discovery, production, characterization, activity and efficacy assessment and development of biologic and diagnostic products. http://www.aragenbio.com

Read the original:
Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process...

Selecta Biosciences Inc (SELB) is near the middle in its industry group according to InvestorsObserver. SELB gets an overall rating of 48. That means it scores higher than 48 percent of stocks. Selecta Biosciences Inc gets a 51 rank in the Biotechnology industry. Biotechnology is number 27 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Selecta Biosciences Inc (SELB) stock is trading at $2.30 as of 9:46 AM on Friday, Oct 16, a rise of $0.19, or 8.79% from the previous closing price of $2.11. The stock has traded between $2.20 and $2.31 so far today. Volume today is below average. So far 223,208 shares have traded compared to average volume of 2,413,171 shares.

Click Here to get the full Stock Score Report on Selecta Biosciences Inc (SELB) Stock.

Excerpt from:
Is Selecta Biosciences Inc (SELB) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Bixink will be responsible for seeking the requisite regulatory approval and, once approved, for commercializing NERLYNX in South Korea. Under the terms of the agreement, Puma will receive upfront and milestone payments of up to $6 million, as well as significant double-digit royalties on the sales of NERLYNX in South Korea.

Our new agreement with Bixink demonstrates our commitment to bringing NERLYNX to patients around the world while continuing to focus our commercial resources on the U.S. market, stated Alan H. Auerbach, Chief Executive Officer and President of Puma. We are excited about the potential to provide South Korean breast cancer patients with access to NERLYNX.

We are excited about the opportunity to provide NERLYNX to patients with HER2-positive breast cancer in South Korea and plan to file for its market authorization before the end of 2020, said Dr. Sung Chul Kim, Chief Executive Officer of Bixink Therapeutics. NERLYNX is our top priority as we aspire to be a leading South Korean company in the field of oncology therapeutics.

Neratinib is approved in the United States for both the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and HER2-positive metastatic breast cancer and is marketed in the United States as NERLYNX (neratinib) tablets.

About HER2-Positive Breast Cancer

Approximately 20% to 25% of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and http://www.NERLYNX.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

About Bixink

Bixink Therapeutics Co. Ltd. is a new South Korean company dedicated towards establishing a new treatment paradigm via converging biotechnology and information technology. Currently focused on the field of anti-cancer drugs and digital therapeutics, Bixink will start commercialization of anti-cancer drug NERLYNX and aims to diligently secure follow up pipeline products, including cancer supportive care and oncologics with novel drug delivery. Bixink also actively seeks various opportunities for collaboration such as co-development and strategic investment to drive its momentum for growth. As one of the pioneers in the field of digital therapeutics in South Korea, Bixink is capable of analysis, R&D, development and validation, and plans to file an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration by the end of this year to launch its first digitalized cognitive behavioral therapy for obsessive compulsive disorder. In the long term, Bixink strives to create a new path by encompassing medicines and digital therapeutics with better clinical outcomes and cost-effectiveness for patients. Bixink strives to push the boundaries of technology to transform medicine.

To find out more about Bixink Therapeutics, please visit http://www.bixink-therapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the international expansion of NERLYNX. All forward-looking statements involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on Pumas business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent reports. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005669/en/

Read more:
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX (neratinib) in South Korea - BioSpace

What happened

Healthcare stocks, on balance, had a great start to the week today. Cancer companies in particular posted strong gains almost across the board Monday. For instance, the stock ofClovis Oncology(NASDAQ:CLVS)ended the day up by 15.2%, shares of Immunomedics (NASDAQ:IMMU) hit a high of 10.2% before ultimately closing up by 8.5%, and Puma Biotechnology(NASDAQ:PBYI)printed a 16.3% gain today.

The odd part to this rising-tide phenomenon is that none of these companies issued a single press release or market-moving Securities and Exchange Commission filing Monday. Instead, this sea of green appears to be the result of institutional investors fleeing weaker parts of the market like oil in favor of safe havens like healthcare. Cancer stocks, after all, should be essentially immune to the economic impacts of the COVID-19 pandemic, given that most patients can't skip out on lifesaving treatments.

Image Source: Getty Images.

If this flight-to-safety thesis is true, then Clovis, Immunomedics, and Puma would arguably all make outstanding vehicles to gain exposure to the high-growth oncology space. Each of these stocks is grossly undervalued relative to its long-term value proposition. Wall Street's 12-month price targets on these names underscore this point nicely. Even after today's sizable moves, for instance, Clovis, Immunomedics, and Puma are still trading well below their 12-month price targets.

Why are these three cancer stocks undervalued right now? Clovis and Puma have both struggled to gain the confidence of investors in this volatile market due to the uncertain commercial outlook for their flagship cancer meds. Immunomedics, on the other hand, scored a major late-stage trial win with itstriple-negative breast cancer drug candidate sacituzumab govitecan earlier this year. Even so, the company's stock has yet to truly price in the full value of this positive clinical outcome, presumably because of the unfavorable market conditions in general.

Are these suddenly red-hot biotech stocks still worth buying? In a word, yes. Clovis should grab an important label expansion for its ovarian cancer med Rubraca later this year, a pivotal event that has the potential to be an inflection point for the company's commercial operations.

Puma, on the other hand, still looks like a decent buy based on the long-term commercial prospects of its breast cancer med Nerlynx. The drug's sales have been slowed down by its onerous side-effect profile, but it should nevertheless still achieve at least $300 million in annual sales. Puma's market cap, by contrast, is only $440 million at the time of this writing.

And Immunomedics stands out as a fantastic buyout target. Triple negative breast cancer is a high-value indication for which few drugs have panned out in clinical studies. Immunomedics, in turn, should fetch a healthy tender offer if sacituzumab govitecan does indeed get the green light from regulators.

More:
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today - Motley Fool

SAN FRANCISCO, June 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the Goldman Sachs 41st Annual Global Healthcare Conference.

Goldman Sachs 41st Annual Global Healthcare Conference

Date: June 11, 2020Fireside Chat Time: 4:40 PM E.T. (updated)Location: Virtual

A live audio webcast of the fireside chat will be available through the Investors & Media section of UNITYs website. An archived replay will be available for 90 days following the event.

About UNITYUNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Investors Endurance AdvisorsMike Zanonimzanoni@enduranceadvisors.com

Media Canale CommunicationsJason Sparkjason@canalecomm.com

See the original post here:
UNITY Biotechnology to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference - GlobeNewswire

Latest market study on Global Gene Therapy Market Forecast to 2027 Covid-19 Impact and Global Analysis By Cell Type (Somatic Gene Therapy, Germline Gene Therapy); By Application (Genetic Disorder, Cancer, Neurological Disorder, and Others).The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Gene Therapy market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

Request Sample Copy of Gene Therapy Market at:https://www.theinsightpartners.com/sample/TIPHE100001165/

Gene therapy is the introduction of DNA into a patient to treat a genetic disease or a disorder. The newly inserted DNA contains a correcting gene to correct the effects of a disease, causing mutations. Gene therapy is a promising treatment for genetic diseases and also includes cystic fibrosis and muscular dystrophy. Gene therapy is a suitable treatment for infectious diseases, inherited disease and cancer.

The growth of the gene therapy market is regulated due to various reason which includes the rapid involvement of synthetically modified gene to treat various diseases, it helps in designing the personalized medicine, rise in the research and development of the gene therapy among the others. The gene therapy requires less doses of medicines and is one time treatment, this factor is likely to show growth opportunity for gene therapy market in coming near future.

Some of the key players profiled in the study areSangamo Therapeutics, Inc., bluebird bio, Inc., uniQure N.V., AveXis, Inc., Vineti, Solid Biosciences., Spark Therapeutics, Inc., CHIMERON BIO, RENOVA THERAPEUTICS, HORAMA S.A., etc.

The research provides answers to the following key questions:

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Medical Device, Pharmaceutical, Healthcare and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Gene Therapy Market globally. This report on Gene Therapy Market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Gene Therapy market. The researcher provides an extensive analysis of the Gene Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Gene Therapy industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Scope of the Report

The research on the Gene Therapy market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Gene Therapy market on the basis of end user, product type, application, and demography for the forecast period 20212027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

Gene Therapy Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @https://www.theinsightpartners.com/buy/TIPHE100001165/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read the original post:
How Gene Therapy Market: Impact Of COVID-19 On Biotechnology Industry Sangamo Therapeutics, Vineti, Solid Biosciences - Medic Insider

The market slump in March has given a great opportunity to acquire stakes in some high-quality business

Polar Capital Healthcare Trust PLC () said that biotechnology is now one of its favourite sectors though it has also added sizeable stakes in pharma giants Roche and Bristol Myers-Squibb because of their strength in oncology.

Issuing its half-year report, the trust added that the market slump due to the coronavirus (COVID-19) crisisin March had also bought a great opportunity to acquire stakes in some high-quality businesses.

That turbulence, though, meant Polars net asset value dropped by 6.4% to 221.7p in the half-year to March, with all the decline was seen in the final month,the FTSE 250-listed trust said

At the end of February, Polar was performing strongly but March saw a drop of 7.1% against a fall in its benchmark index of 0.64%. Polar noted that it was affected by being overweight in mid-capitalisation stocks, with an emphasis on Europe and the US also a drag.

Going forward, the trust said that, as wellas biotechnology, it is also over-weight in life sciences tools and services, reflecting its view that the challenges facing the end markets from COVID-19 are transient.

Indeed, not only is the Asia Pacific region starting to show the green shoots of recovery, the industry has been heavily involved in the development and manufacture of testing kits to help manage the COVID-19 crisis, it said.

The trust added: In an uncertain world, the resilient growth profile of the healthcare sector offers appeal, with financially sound large-capitalisation companies especially well-positioned. At the same time, the political backdrop is supportive, valuations in the US are attractive.

Net assets at the end of March were valued at 267mln.

View original post here:
Polar Cap Healthcare Trust overweight in biotechnology as it looks post-coronavirus pandemic - Proactive Investors UK

Global Biotechnology Market Growth Projection

The new report on the global Biotechnology market is an extensive study on the overall prospects of the Biotechnology market over the assessment period. Further, the report provides a thorough understanding of the key dynamics of the Biotechnology market including the current trends, opportunities, drivers, and restraints. The report introspects the micro and macro-economic factors that are expected to nurture the growth of the Biotechnology market in the upcoming years and the impact of the COVID-19 pandemic on the Biotechnology . In addition, the report offers valuable insights pertaining to the supply chain challenges market players are likely to face in the upcoming months and solutions to tackle the same.

The report suggests that the global Biotechnology market is projected to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key indicators such as the year-on-year (Y-o-Y) growth and CAGR growth of the Biotechnology market are discussed in detail in the presented report. This data is likely to provide readers an understanding of qualitative and quantitative growth prospects of the Biotechnology market over the considered assessment period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2635118&source=atm

The report clarifies the following doubts related to the Biotechnology market:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2635118&source=atm

Segmentation of the Biotechnology Market

The key players covered in this studyJohnson & Johnson Services, Inc.F. Hoffmann-La Roche LtdPfizerMerck &SanofiAstraZenecaGileadCELGENE CORPORATIONBiogenAmgen, IncAbbottNovo Nordisk A/SNovartis AGLonza

Market segment by Type, the product can be split intoDNA SequencingNanobiotechnologyTissue engineering and RegenerationFermentationCell Based AssayPCR TechnologyChromatography MarketOthersMarket segment by Application, split intoHealthFood & AgricultureNatural Resources & EnvironmentIndustrial ProcessingBioinformaticsOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Biotechnology status, future forecast, growth opportunity, key market and key players.To present the Biotechnology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Biotechnology are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2635118&licType=S&source=atm

Vital Information Enclosed in the Report

Continue reading here:
Addressing the potential impact of coronavirus disease (COVID-19) on Biotechnology Market : Global Analysis and Opportunity Assessment 2019-2027 -...

A recent research on Biotechnology and Pharmaceutical Services Outsourcing market, now available with Market Study Report, LLC, is a thorough study on the latest market trends prevailing in the global business sphere. The report also offers important details pertaining to market share, market size, profit estimations, applications and statistics of this industry. The report further presents a detailed competitive analysis including growth strategies adopted by key players of the industry.

This Biotechnology and Pharmaceutical Services Outsourcing market study report includes a detailed extract of this industry incorporating a number of vital parameters. Some of them relate to the current scenario of this marketplace as well as the industry scenario over the forecast timeframe. Including all the key development trends characterizing the Biotechnology and Pharmaceutical Services Outsourcing market, this evaluated report also contains many other pointers like the present industry policies and topographical industry layout characteristics. Additionally, the report also contains the impact of the present market scenario of the investors.

Request a sample Report of Biotechnology and Pharmaceutical Services Outsourcing Market at:https://www.marketstudyreport.com/request-a-sample/2671102?utm_source=newsdistinct.com&utm_medium=sp

This report includes details about the enterprise competition trends, advantages and disadvantages of the enterprise products as well as a detailed scientific analysis of the raw material and industry downstream buyers among some of the parameters.

Categorizing the competitive landscape of the industry

.

Assisting prominent stakeholders with regional landscape information

Ask for Discount on Biotechnology and Pharmaceutical Services Outsourcing Market Report at:https://www.marketstudyreport.com/check-for-discount/2671102?utm_source=newsdistinct.com&utm_medium=sp

Additional key aspects included in the Biotechnology and Pharmaceutical Services Outsourcing market study:

.

.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-biotechnology-and-pharmaceutical-services-outsourcing-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries

Some of the Major Highlights of TOC covers:

Biotechnology and Pharmaceutical Services Outsourcing Regional Market Analysis

Biotechnology and Pharmaceutical Services Outsourcing Segment Market Analysis (by Type)

Biotechnology and Pharmaceutical Services Outsourcing Segment Market Analysis (by Application)

Biotechnology and Pharmaceutical Services Outsourcing Major Manufacturers Analysis

Related Reports:

1. Global Wound Care Sealants Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and CountriesThis report categorizes the Wound Care Sealants market data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors Analysis.Read More: https://www.marketstudyreport.com/reports/global-wound-care-sealants-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries

2. Global Piccolo Trumpets Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and CountriesPiccolo Trumpets Market Report covers the makers information, including shipment, value, income, net benefit, talk with record, business appropriation and so forth., this information enables the buyer to think about the contenders better. This report additionally covers every one of the districts and nations of the world, which demonstrates a provincial advancement status, including market size, volume and esteem, and also value information. It additionally covers diverse enterprises customers data, which is critical for the producers.Read More: https://www.marketstudyreport.com/reports/global-piccolo-trumpets-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Visit link:
Biotechnology and Pharmaceutical Services Outsourcing Market to 2027: Growth Analysis by Manufacturers, Regions, Types and Applications - News...

Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.

In contrast to all current vaccination approaches against SARS-Co-V-2, the approach of Mirror Biologics Inc., the US subsidiary of Jerusalem-based Immunovative Therapies Ltd., addresses the phenomenon of viral evolution. In the Journal of Translational Medicine, Michael Har-Noy and collegues describe the companies technical rationale for development of a universal anti-viral vaccine designed to protect immunocompromised humans and eldery adults from COVID-19 and any future novel virus outbreaks.

The patent-pending technology called AlloPriming is designed so that a series of injections of bioengineered Th1-cells, called AlloStim, could provide protection from any future viral infection, including progression of the current outbreak of COVID-19 infection, and any future variants of the causative SARS-CoV-2 virus or the next Disease X. The technology primes the elderly immune system to respond to viruses in the same manner as a healthy younger adult immune system would respond it remodels the aging immune system in order to reverse immunosenescence and protect against chronic inflammations. A Phase I/II clinical protocol has been prepared for testing this concept in healthy adults over 50 years in age and is currently under review by the US FDA.

The major focus for vaccine development against viruses are currently strategies that introduce inactivated whole viruses, or pieces of viruses, or viral genetic material to teach the immune system to make antibodies, which bind to the virus. The aim is to elicit antibodies which neutralize the virus by blocking entry into host cells. According to the authors, allo-priming, which triggers call-based immunity, provides a back-up in case vaccination strategies to elicit neutralising antibody protection fails or fails to protect the vulnerable elderly population.

Allo-priming is performed using activated, intentionally mismatched, ex vivo differentiated and expanded living Th1-like cells (AlloStim) derived from healthy donors. Preclinically, multiple intradermal injections of AlloStimcreated a dominate titer of allo-specific Th1/CD8-T-cytotoxic memory cells in circulation, replacing the dominance of exhausted memory cells of the aged immune system. Upon viral encounter, by-stander activation of the allo-specific memory cells caused an immediate release of interferon gamma (IFN-), stopping viral transcription and leading to by-stander activation of innate cellular effector cells and activation of cross-reactive allo-specific CD8-T-cytotoxic lymphocytes.

A youthful immune response is believed to be most capable of clearance of viral infections before the infection progresses to serious disease", said Reuven or, who co-authored the publication. He sees the approach as complementary to current vaccination approaches. But in deed it is more:

All current vaccination approaches have not been successful in protecting against emergent viruses, such as HIV, hepatitis C, Zika, dengue and the pandemic SARS and MERS coronaviruses, which mutatate and adapt very rapidly to its hosts. In contrast to childhood diseases they will not provide lifelong protection because they are based on an approach viral evolution, which does not occur in pathogens such as measles or other childhood diseases. For this reason, current vaccine technology platforms may not timely produce a protective vaccine against COVID-19 or could result in a vaccine that becomes obsolete after a viral mutation.

What is currently widely ignored: traditional vaccines could make rapidly mutating and adapting pathogens more aggressive. Under normal conditions, viral pathogens never become extremely deadly because they only spread if most of their hosts survive the infection. As vaccines create a selection advantage for viruses, which could enter and reproduce themselves ultrarapidly in the host cell, they might trigger a kind of vaccine-driven evolution, which would make viruses more deadly and devasting as postulated for the case of Marek's disease vaccines a neoplastic disease of poultry.

Lead author Michael Har-Noy commented: "While there is great optimism regarding current clinical trials investigating protective vaccines against COVID-19, there is a very real possibility that none of the vaccine candidates under investigation will prove to provide long-term protection from COVID-19, and some vaccine candidates may even make symptoms worse. Even in the event that an effective vaccine is timely developed, such a vaccine likely would not be as effective in providing protective immunity in the elderly. If allo-priming is proven to work as designed, a single series of shots could protect against the current pandemic as well as any future pandemic.

More:
Vaccine to protect from any viral infection - European Biotechnology